New hope for stomach cancer patients who've run out of options?
NCT ID NCT07364422
First seen Jan 26, 2026 · Last updated May 02, 2026 · Updated 16 times
Summary
This study tests a new drug, JPI-547, combined with the chemotherapy irinotecan for people with advanced stomach cancer that has come back or spread. It is for patients who have already tried at least two other treatments. The goal is to see if the combination is safe and can shrink tumors. About 49 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER (GC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, South Korea
Contact
Conditions
Explore the condition pages connected to this study.